BACKGROUND: Closed-loop insulin delivery is a promising option to improve glycaemic control and reduce the risk of hypoglycaemia. We aimed to assess whether overnight home use of automated closed-loop insulin delivery would improve glucose control. METHODS: We did this open-label, multicentre, randomised controlled, crossover study between Dec 1, 2012, and Dec 23, 2014, recruiting patients from three centres in the UK. Patients aged 18 years or older with type 1 diabetes were randomly assigned to receive 4 weeks of overnight closed-loop insulin delivery (using a model-predictive control algorithm to direct insulin delivery), then 4 weeks of insulin pump therapy (in which participants used real-time display of continuous glucose monitoring independent of their pumps as control), or vice versa. Allocation to initial treatment group was by computer-generated permuted block randomisation. Each treatment period was separated by a 3-4 week washout period. The primary outcome was time spent in the target glucose range of 3·9-8·0 mmol/L between 0000 h and 0700 h. Analyses were by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT01440140. FINDINGS: We randomly assigned 25 participants to initial treatment in either the closed-loop group or the control group, patients were later crossed over into the other group; one patient from the closed-loop group withdrew consent after randomisation, and data for 24 patients were analysed. Closed loop was used over a median of 8·3 h (IQR 6·0-9·6) on 555 (86%) of 644 nights. The proportion of time when overnight glucose was in target range was significantly higher during the closed-loop period compared to during the control period (mean difference between groups 13·5%, 95% CI 7·3-19·7; p=0·0002). We noted no severe hypoglycaemic episodes during the control period compared with two episodes during the closed-loop period; these episodes were not related to closed-loop algorithm instructions. INTERPRETATION: Unsupervised overnight closed-loop insulin delivery at home is feasible and could improve glucose control in adults with type 1 diabetes. FUNDING: Diabetes UK.
BACKGROUND: Closed-loop insulin delivery is a promising option to improve glycaemic control and reduce the risk of hypoglycaemia. We aimed to assess whether overnight home use of automated closed-loop insulin delivery would improve glucose control. METHODS: We did this open-label, multicentre, randomised controlled, crossover study between Dec 1, 2012, and Dec 23, 2014, recruiting patients from three centres in the UK. Patients aged 18 years or older with type 1 diabetes were randomly assigned to receive 4 weeks of overnight closed-loop insulin delivery (using a model-predictive control algorithm to direct insulin delivery), then 4 weeks of insulin pump therapy (in which participants used real-time display of continuous glucose monitoring independent of their pumps as control), or vice versa. Allocation to initial treatment group was by computer-generated permuted block randomisation. Each treatment period was separated by a 3-4 week washout period. The primary outcome was time spent in the target glucose range of 3·9-8·0 mmol/L between 0000 h and 0700 h. Analyses were by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT01440140. FINDINGS: We randomly assigned 25 participants to initial treatment in either the closed-loop group or the control group, patients were later crossed over into the other group; one patient from the closed-loop group withdrew consent after randomisation, and data for 24 patients were analysed. Closed loop was used over a median of 8·3 h (IQR 6·0-9·6) on 555 (86%) of 644 nights. The proportion of time when overnight glucose was in target range was significantly higher during the closed-loop period compared to during the control period (mean difference between groups 13·5%, 95% CI 7·3-19·7; p=0·0002). We noted no severe hypoglycaemic episodes during the control period compared with two episodes during the closed-loop period; these episodes were not related to closed-loop algorithm instructions. INTERPRETATION: Unsupervised overnight closed-loop insulin delivery at home is feasible and could improve glucose control in adults with type 1 diabetes. FUNDING: Diabetes UK.
Authors: Roman Hovorka; Janet M Allen; Daniela Elleri; Ludovic J Chassin; Julie Harris; Dongyuan Xing; Craig Kollman; Tomas Hovorka; Anne Mette F Larsen; Marianna Nodale; Alessandra De Palma; Malgorzata E Wilinska; Carlo L Acerini; David B Dunger Journal: Lancet Date: 2010-02-04 Impact factor: 79.321
Authors: Malgorzata E Wilinska; Ludovic J Chassin; Carlo L Acerini; Janet M Allen; David B Dunger; Roman Hovorka Journal: J Diabetes Sci Technol Date: 2010-01-01
Authors: Roman Hovorka; Daniela Elleri; Hood Thabit; Janet M Allen; Lalantha Leelarathna; Ranna El-Khairi; Kavita Kumareswaran; Karen Caldwell; Peter Calhoun; Craig Kollman; Helen R Murphy; Carlo L Acerini; Malgorzata E Wilinska; Marianna Nodale; David B Dunger Journal: Diabetes Care Date: 2014 Impact factor: 19.112
Authors: Boris P Kovatchev; Eric Renard; Claudio Cobelli; Howard C Zisser; Patrick Keith-Hynes; Stacey M Anderson; Sue A Brown; Daniel R Chernavvsky; Marc D Breton; Anne Farret; Marie-Josée Pelletier; Jérôme Place; Daniela Bruttomesso; Simone Del Favero; Roberto Visentin; Alessio Filippi; Rachele Scotton; Angelo Avogaro; Francis J Doyle Journal: Diabetes Care Date: 2013-07 Impact factor: 19.112
Authors: Roman Hovorka; Kavita Kumareswaran; Julie Harris; Janet M Allen; Daniela Elleri; Dongyuan Xing; Craig Kollman; Marianna Nodale; Helen R Murphy; David B Dunger; Stephanie A Amiel; Simon R Heller; Malgorzata E Wilinska; Mark L Evans Journal: BMJ Date: 2011-04-13
Authors: Trang T Ly; Jennifer A Nicholas; Adam Retterath; Elizabeth A Davis; Timothy W Jones Journal: Diabetes Care Date: 2012-05-14 Impact factor: 19.112
Authors: Amanda J Young; Hood Thabit; Simon R Heller; Mark L Evans; Stephanie A Amiel; Roman Hovorka; Katharine D Barnard Journal: J Diabetes Sci Technol Date: 2015-04-07
Authors: Sue A Brown; Marc D Breton; Stacey M Anderson; Laura Kollar; Patrick Keith-Hynes; Carol J Levy; David W Lam; Camilla Levister; Nihat Baysal; Yogish C Kudva; Ananda Basu; Vikash Dadlani; Ling Hinshaw; Shelly McCrady-Spitzer; Daniela Bruttomesso; Roberto Visentin; Silvia Galasso; Simone Del Favero; Yenny Leal; Federico Boscari; Angelo Avogaro; Claudio Cobelli; Boris P Kovatchev Journal: J Clin Endocrinol Metab Date: 2017-10-01 Impact factor: 5.958
Authors: Stacey M Anderson; Eyal Dassau; Dan Raghinaru; John Lum; Sue A Brown; Jordan E Pinsker; Mei Mei Church; Carol Levy; David Lam; Yogish C Kudva; Bruce Buckingham; Gregory P Forlenza; R Paul Wadwa; Lori Laffel; Francis J Doyle; J Hans DeVries; Eric Renard; Claudio Cobelli; Federico Boscari; Simone Del Favero; Boris P Kovatchev Journal: Diabetes Technol Ther Date: 2019-01-16 Impact factor: 6.118
Authors: Clara Mosquera-Lopez; Robert Dodier; Nichole S Tyler; Leah M Wilson; Joseph El Youssef; Jessica R Castle; Peter G Jacobs Journal: Diabetes Technol Ther Date: 2020-05-14 Impact factor: 6.118
Authors: Darrell M Wilson; Peter M Calhoun; David M Maahs; H Peter Chase; Laurel Messer; Bruce A Buckingham; Tandy Aye; Paula K Clinton; Irene Hramiak; Craig Kollman; Roy W Beck Journal: Diabetes Technol Ther Date: 2015-03-11 Impact factor: 6.118